Table 9 Summary of cost-effectiveness results, by study arm
| Â | Effectiveness, per 1000 clients | Costs per DALY averted, US$ | ||||||
|---|---|---|---|---|---|---|---|---|
HIV/AIDS | Cervical cancer | Â | ||||||
Deaths | DALYs | Deaths | DALYs | HTC | VMMC | HIV C&T | CCS | |
Study arm | ||||||||
 SOC | 4160 | 96796 | 3765 | 83966 | — | — | — |  |
 Arm 2 | 4240 | 83970 | 3350 | 78808 | $ 7890 | $ 377 | $ 81 | $ 607 |
 Arm 3 | 3708 | 65078 | 3254 | 77741 | $ 3180 | $ 162 | $ 33 | $ 106 |
Difference | Deaths averted | DALYs | Deaths averted | DALYs | Â | Â | Â | Â |
 SOC – Arm2 | −80 | 12826 | 415 | 5157 |  |  |  |  |
 SOC – Arm 3 | 452 | 31718 | 511 | 6224 |  |  |  |  |